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Sickle cell disease (SCD) is one of the most prevalent monogenic hereditary 
diseases in Brazil and worldwide, being considered an important public health 
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The objective of this study was to evaluate the access, assistance 
and satisfaction of people with sickle cell disease in relation to 
the health care provided by the Unified Health System in 
Uberlândia city, Minas Gerais, Brazil. Thirty-four people with 
sickle cell disease were recruited using the snowball sampling 
method and submitted to semi-structured interview in which 
demographic, clinical, relationship and satisfaction with health 
care were collected. Forty-four percent were not included in the 
Primary Health Care network, which did not provide several 
procedures/actions recommended by the Ministry of Health. 
Ninety-four percent were unsatisfied/partially satisfied with the 
emergency care provided in the Integrated Care Units. The main 
reasons for the unsatisfied were ignorance of sickle cell disease by 
the health team (87.5%), delay in care (81.3%) and inadequate 
conduct by the health team (59.5%). In conclusion, the access 
and quality of care provided to people with sickle cell disease by 
the Primary Health Care network and the Urgency and 
Emergency Network need to be improved and this improvement 
is directly related to the training of health teams. 
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problem [1-3]. Originally from Africa, it was brought to Brazil by the forced 
migration of slaves, most often affecting black and brown people. According to 
the National Neonatal Screening Program, it’s estimated that 3,500 children with 
SCD and 200,000 with sickle cell trait are born in Brazil each year [4,5]. 
Transmitted in an autosomal recessive pattern, SCD results from a mutation 
in the beta-globin gene, with the formation of an anomalous hemoglobin called 
hemoglobin S (HbS). In addition, SCD encompasses a group of 
hemoglobinopathies in which the HbS gene is present in homozygosis (SS 
genotype) or in compound heterozygosis that is combined with another 
hemoglobin variant such as hemoglobin C (SC genotype), β-thalassemia (Sβ 
genotypes), hemoglobin E (SE genotype) and others rarer. The SS genotype has a 
more severe clinical significance, being called sickle cell anemia (SCA) [6-8]. 
The HbS has altered physical and chemical properties, showing a propensity 
to undergo polymerization under conditions of low oxygen tension, which leads to 
alteration of red blood cell shape (sickle shape). Sickle red blood cells present 
several changes in their membrane, becoming rigid, more mechanically fragile, 
therefore, more susceptible to intravascular hemolysis and with increased 
adhesion to endothelial cells, leukocytes and platelets. Thus, they are easily 
trapped in places with slower microcirculation, generating acute vasoocclusive 
events with ischemic and reperfusion injuries in various organs and tissues [9,10].  
The most relevant clinical events of the disease are acute and recurrent crises 
of pain, chronic hemolytic anemia, progressive impairment and insufficiency of 
multiple organs. These manifestations, despite varying from individual to 
individual, are potentially devastating and, in general, have important 
repercussions in various aspects of a person's life, it may even reduce life 
expectancy [11-14]. Thus, as a chronic disease, which persists throughout life, 
usually incurable, but treatable, SCD causes its carrier to require careful and 
continuous assistance by a multidisciplinary health team. This assistance, when 
properly performed, promotes morbidity and mortality reduction with an 
improvement in life’s quality and an increase in life expectancy [15-17]. 
In order to ensure that person with SCD has adequate access, reception and 
assistance in health services that are part of the Unified Health System (UHS), 
the Ministry of Health of Brazil published several ordinances that defined the 
guidelines of the National Policy for Comprehensive Care for People with Sickle 
Cell Disease [18]. These guidelines include diagnostic, prophylactic, propaedeutic 
and therapeutic actions. It was postulated that Primary Health Care Network 
(PHCN) should be the preferred gateway for people with SCD in to the health 
system, with Family Health Strategy (FHS) team as the organizing center for all 
services in all assistance levels (low, medium and high complexity). Basic Health 
Care (BHC) units must be integrated with specialized care reference centers and 
coordinate the necessary care. Various clinical protocols and therapeutic 
guidelines were also developed to qualify this care and it was determined that, at 
all levels of care, the qualification and continuing education of health 
professionals involved in this care should be promoted [19-22]. 
This study aimed to assess the access, assistance and satisfaction of people 
with SCD relation to health care provided by the UHS network in the Uberlândia 
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This is a descriptive, cross-sectional, quali-quantitative study in which people 
with SCD who lived in the Uberlândia city participated. 
Uberlândia city is located in the southeast of Brazil being the second largest 
city in population in Minas Gerais state, estimated 691,305 inhabitants by the 
Brazilian Institute of Geography and Statistics in 2019 [23]. According to a report 
made available by the website of the National Register of Health Establishments 
[24], the Public Health network of Uberlândia city, that provides services to UHS, 
has 56 Family Health Teams (FHT), 12 conventional Basic Health Units (BHU), 
8 Integrated Care Units (ICU), an university hospital (belonging to the Federal 
University of Uberlândia) and a Blood Center (belonging to the Hemominas 
Foundation), providing assistance at the level of primary care and complexity 
medium and high.  
 
 
Participants recruitment  
 
Participants were recruited using the snowball sampling technique [25] in 
which, briefly, a key informant, known to have SCD, was found.This person was 
asked to indicate the contact of other people who also had the disease. The 




Sample size determination 
 
The methodology proposed by Fonseca & Martins was used to sample size 
determination [26]. Knowing that Uberlândia city population in the age group 
between 18 and 54 years old is approximately 400,000 people [23], that the 
incidence rate of SCD in Minas Gerais state is around 1:1400 live births [27] and 
that a sampling precision of 1% around the central value and a 95% confidence 






Thirty-four people with SCD participated in the study, who met the inclusion 
criteria: being 18 years of age or older (laboral age), living in Uberlândia city and 
not having cognitive impairment or having other relevant chronic diseases not 
related to SCD. All of them had a SCD diagnosis confirmed by the hemoglobin 
electrophoresis test, performed previously at some time in their lives, whose result 
(genotype) was in the data in the Blood Center’s registry. After signing a free 
and informed consent form, they were submitted to a semi-structured interview, 
with collection of demographic, clinical, relationship and satisfaction data with 
healthcare. The interviews were conducted from November 2018 to January 2019. 
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Analysis 
 
The data obtained were recorded in a Microsoft Excel electronic data base 
and submitted to an exploratory descriptive statistical analysis (frequencies and 
percentages for categorical variables and measures of central tendency and 




Ethics committee  
 
All experimental procedures were approved by Research Ethics Committee 





 The thirty-four participants were aged between 18 to 70 years old, with an 
average age of 35.82 ± 15.29 years old. Only one (2.9%) was 70 years old and 
about 65% was 40 years old or younger. Regarding gender, 55,9% of the sample 
was male. The majority (79.4%) had black or brown skin (Table 1). Eighteen 
individuals (53.9%) had completed high school. Of these, five (14.7%) were in 
higher education and one (2.9%) had already completed it. Eleven people (32.4%) 
had only elementary education and of these, seven (20.6%) did not complete it. 
The most common hemoglobin genotype was SS (64.7%) and eight people 
(23.5%) had their diagnosis established by neonatal screening (Heel Prick Test). 
Thirty-three (97.1%) had already been hospitalized due to complications related 
to SCD. Fifteen participants (44.1%) used hydroxyurea (Table 1).  
 
Table 1: Demographic characteristics of the participants and use of hydroxyurea in relation to the 
disease genotype. 
Characteristics of the 
participants 
Genotype 








































8 (23,5 ) 
7 (20,6) 
Age group (years)  
18 - 21  
22 - 49  
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Regarding access and use of health system, 15 participants (44.1%) weren’t 
included in Primary Health Care network as a result of living in areas without 
coverage. This contrasted with the monitoring at the Specialized Service, carried 
out by the Regional Blood Center of Uberlândia, in which 32 people (94.1%) were 
followed up. The 19 participants (55.9%) inserted in the BHC were questioned 
regarding the availability by this network of the procedures and actions 
recommended by the Ministry of Health (Table 2). 
 
Table 2: Availability in the Basic Health Units (BHU) and Basic Family Health Units (BFHU) of 
the procedures/actions recommended by the Ministry of Health. 
 





Do not know 
N (%) 
Total=19 
Electrophoresis Hb 9 (47,4)  0 (0) 10 (52,6)  
Sickle cell trait orientation 17 (89,4) 1 (5,3) 1 (5,3)  
Forwarding of exams requested  
























Wound prevention and forwarding  








Link maintenance 17 (89,5) 2 (10,5) 0 (0)  









Promotion of social inclusion 17 (89,5) 0 (0) 2 (10,5)  
* About 80% of patients who stated that BHC conducts the examinations requested by the Specialized Service also 
reported that they enter a waiting list with an average delay of 2 years for the examinations. 
** The units' pharmacies only supply medicines when they are made available by the municipality, which is not always 
the case. 
 
Emergency care is provided by ICU and when asked about satisfaction with 
this service, only two participants (5.9%) were satisfied, 20 (58.8%) were 
unsatisfied and 12 (35.3%) partially satisfied (Table 3). The main reasons, 
spontaneously reported, for this unsatisfied/partial satisfaction were, in 
decreasing order, ignorance of SCD by the health team, delay in service and 
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Table 3: Satisfaction of study participants with urgent/emergency care in Integrated Care Units 
(ICU) and Specialized Service (Hemocentro). 
Service Satisfaction 

































Table 4: Main reasons for unsatisfied/partially satisfied of 32 study participants in relation to 
emergency care in Integrated Care Units (ICU). 
Reasons for unsatisfied/partially satisfied N (%) 
Not knowledge of sickle cell disease by the health team 28 (87,5) 
Service delay 26 (81,3) 
Inappropriate conduct by the health team 19 (59,5) 
Lack of unit structure 15 (46,9) 
 
 
Between 32 participants accompanied by the Specialized Service, 24 (75%) are 
satisfied with this service and eight (25%) partially satisfied (Table 3). The 
partially satisfied ones complained of difficulty in understanding the language 
used in the orientation (33.3%), unpreparedness of the physiotherapy team 
(22.2%) and precarious resources for dental treatment (11.1%) (Table 5). 
 
Table 5: Main reasons for the partial satisfaction of eight study participants in relation to 
attendance at the Specialized Service (Hemocentro). 
Reasons for partially satisfied N (%) 
Difficulty understanding the language used in orientation 26 (33,3) 
Lack of preparation of the physiotherapy team 15 (22) 





 Our study included only people with SCD who were at least 18 years old and 
didn’t have cognitive deficits. These two criteria associated with the fact that 
most of them (53.9%) had completed high school suggest that the reports and 
opinions they issue are consistent with the realities experienced. 
 The slight predominance of the male gender was also observed in Fernandes’s 
study and colleagues [28] , in which 52.8% of children hospitalized with SCD were 
of the same gender. On the other hand, some studies show higher prevalence of 
females [29,30], demonstrating that SCD is a genetic disease not linked to sex.
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The highest frequency of the SS genotype (sickle cell anemia) among the 
participants is in line with the fact that it’s the most frequent worldwide [7]. 
Similarly, confirming what is already observed worldwide, a greater number of 
blacks and browns people affected by the disease were also found. This finding is 
relevant to the extent that this population group has, in general, the worst 
epidemiological, educational and economic indicators, which contributes to a 
worse prognosis of the disease [11,31]. 
 Interestingly, seven people (20.6%) aged between 50 and 70 years were found 
and among them, three were considered elderly (aged 60 or more). This is a 
curious fact because it’s an unusual finding in SCD.  
In a study that evaluated 3,764 people with SCD, that the median age at the 
time of death for patients with the SS genotype was 42 years for men and 48 
years for women and 60 years for men and 68 years for women with SC genotype 
[32]. These data corroborate our findings, since the three elderly individuals had 
the SC genotype.  
 All participants, except one, had already been hospitalized. This single 
exception corresponded to the 70 year old individual with the SC genotype and 
can be explained by the clinical variability of the disease. This variability can be 
associated with genetic factors, such as genotype and environmental factors, such 
as socioeconomic status, place of residence, access and quality of medical care and 
prevalence of infectious diseases [15]. 
 In Minas Gerais state, the State Neonatal Screening Program (Heel Prick 
Test) implemented screening for hemoglobinopathies in March 1998, so it has 
been 21 years in relation to this study. In recent years, 98% of newborns in Minas 
Gerais state have neonatal screening. The objective of this program, in addition 
to the early diagnosis of SCD, the institution of adequate treatment and 
prophylactic measures that contribute to a significant morbidity and mortality 
reduction [33]. In our study, 75% of participants aged between 18 to 21 years old 
had their diagnosis confirmed by this procedure, reflecting the initial results of 
implementing the program in Uberlândia city. 
Hydroxyurea is a chemotherapeutic agent, myelosuppressant, it’s currently the 
only drug with proven efficacy in the treatment of SCD. Some of the benefits 
resulting from the hydroxyurea use in SCD are reduced frequency of painful 
episodes, reduced transfusion needs and episodes of acute chest syndrome, 
increased production of fetal hemoglobin (HbF) and decreased risk of death.  
Possible adverse effects from its use include neutropenia, bone marrow 
suppression, elevated liver enzymes, anorexia, nausea, vomiting and infertility 
[34,35]. 
 In our study, about 44% of participants were using hydroxyurea. Between 
these participants, 80% had the SS genotype and the others the SC genotype. 
This finding is justified since the clinical severity of SCD in patients with the SS 
genotype (sickle cell anemia) is generally greater [15,36] and the prescription of 
hydroxyurea follow the mandatory presence of some inclusion criteria. Among 
these is the occurrence, in the last 12 months, of at least one of a list of 
complications such as: three or more acute pain episodes requiring medical 
attention, more than one event of acute chest syndrome, chronic hypoxemia, 
chronic organ injury proven, Hb < 7g/dL out of acute event, HbF concentration 
< 8% after 2 years old, leukocyte count > 20,000/mm3, lactic dehydrogenase 
levels twice above the reference value for age and changes in transcranial 
echocardiography [37]. This means that at least 44% of the survey participants 
had at least one of these complications. 
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 Accessibility to health care can be understood as the ability to generate 
services and meet the health demands for a given group, including the 
characteristics of services and resources that facilitate or prevent their use by 
users. Therefore, access to a health service or service network is influenced by 
multiple factors such as geographic, organizational, socio-cultural and economic 
[38]. 
In the present study it was observed that the access of people with SCD to 
the Primary Health Care network in Uberlândia city is seriously compromised, 
since a significant portion of the study participants (44.1%) is not included in this 
network in due, among other reasons, to living in places without coverage.  On 
the other hand, we found that 94.1% of the studied population is served by the 
Specialized Service, represented by the Blood Center, regardless of whether they 
live at a reasonable distance from this institution. This is nothing new, repeating 
what was observed in other studies carried out in various parts of the country. 
One of the reasons postulated for this is that historically the treatment of SCD is 
considered as the competence of hematological centers [11,39].  
Perceptibly, there are other reasons for this to happen, which is evident when 
we analyze satisfaction with the services provided by BHC and the Blood Center. 
The number of unsatisfied/partially satisfied with the assistance provided by 
BHC was very expressive (94.1%), in contrast to the also expressive satisfaction 
(75.0%) shown in relation to the Blood Center. Spontaneous reporting of reasons 
for unsatisfied/partial satisfaction allows for a better understanding of the care 
situation as a whole. The most frequent complaints, in relation specifically to the 
emergency care provided by ICU, and the reports in the literature refer us to 
some possible basic reasons for these occurrences: failure in the humanization 
process of service and unpreparedness of the health teams to care for the person 
with SCD. This unpreparedness is undoubtedly result of training lack of health 
teams, which perpetuates the status of ignorance the disease and significantly 
limits the possibility of providing comprehensive and adequate assistance to 
people with SCD.  
The manual “Sickle Cell Disease - Basic Guidelines for the Care Line”, 
prepared by Ministry of Health [18], postulates that humanization must be based 
on providing a comfortable environment for care of people. These must be 
received in a caring and supportive manner, without showing prejudices and 
stigmas; they must be attentively listened, communication must be respectful and 
accessible language, easy to understand to the lay public should be used. 
Classically, people with SCD have recurrent and disabling pain episodes. 
Worldwide there are numerous publications with reports of stigmatization of 
adults with SCD in health system, such as health professionals whose generally 
insensitive to their experience of pain. People with SCD are often seen by the 
health team as drug addicts. These negative experiences with health care make 
many of these people delay the search for medical care managing their episodes of 
pain at home. Therefore, having prior guidance to be able to perceive and 
understand the pain experience of the person with SCD and to properly welcome 
them is the first step to improve access and assistance to this population [13,40]. 
 The second most frequent complaint of the study participants refers to the 
delay in attending when they sought the ICU emergency service. The 
investigation and recognition of warning signs in patients with SCD make their 
care a priority. This suggests that health teams are not prepared to recognize the 
signs and needs in care of people with SCD [38,39,41]. It’s noteworthy that 
participants themselves detected the lack of knowledge of the health team. This 
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was the main reason cited by them for their dissatisfaction with emergency care 
and inadequate treatment.  
As previously mentioned, economic and organizational factors also influence 
the access and efficiency of a health service [39]. Perhaps these two factors were 
preponderant in determining the findings regarding the availability of 
procedures/actions (recommended by the Ministry of Health) in Basic Health 
Unit and Basic Family Health Unit (BFHU). Procedures/actions such as: 
informing the user that the network provides hemoglobin electrophoresis test for 
relatives and partner, promoting the maintenance of the bond through regular 
visits, providing guidance on the sickle cell trait and the disease, performing the 
preventing wounds, identifying and forwarding urgencies/emergencies, which are 
not being carried out or carried out minimally, probably depend more on 
organizational procedures and training of the health team than economic factors. 
These procedures/actions are relevant, as they change attitudes and decrease 
physical, emotional and social problems resulting from the disease [15,39,42]. 
 A limitation of our study is due to the sampling method used (snowball 
sampling method), which may have led to the constitution of a sample that is not 





The unsatisfied shown by SCD patients in relation to care provided by Public 
Health System demonstrates important deficiencies in management and provision  
services by health system and need for both access and quality of care to be 
improved. This unsatisfied was greater in assistance provided by Primary Health 
Care and in attendance to emergencies/urgencies, practically not being verified in 
relation to specialized service linked to Hemocentro, which for this reason is the 
most sought by patients. 
The lack of knowledge about the disease, the unpreparedness and the 
inadequate conduct of health teams, as well as the failures in reception, identified 
by SCD patients as relevant to their unsatisfied, demand urgent and effective 
interventions. It is essential to implement organizational and training procedures 
of health teams of BHC, FHT and ICU which guarantee qualified assistance to 
SCD patients allowing a better quality of life and avoiding suffering, serious and 
disabling sequelae. 
In conclusion, the performance of public health managers, municipal and 
state, who have knowledge of situation, promote the training of health 
professionals and their humanized acting, use mechanisms to monitor the 
performance and efficiency these professionals and create strategies to provide in 
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